| P50 | author | Charles A Powell | Q57195831 |
| P2093 | author name string | Balazs Halmos | |
| | Haiying Cheng | |
| | Alain C Borczuk | |
| | Antai Wang | |
| | Mahesh M Mansukhani | |
| | Catherine Shu | |
| P2860 | cites work | Clinicopathologic characteristics of adenosquamous carcinoma of the lung | Q68179265 |
| | Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung | Q73565215 |
| | Adenosquamous carcinoma of the lung. Surgical results compared with squamous cell and adenocarcinoma | Q74641922 |
| | Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase | Q80218915 |
| | Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 |
| | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
| | KRAS mutations in non-small cell lung cancer | Q28240568 |
| | Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 |
| | Lung cancer | Q28243164 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 |
| | Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 |
| | Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population | Q33820536 |
| | Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer | Q34323659 |
| | Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. | Q34330363 |
| | Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 |
| | Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung | Q35809964 |
| | Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways | Q35843403 |
| | Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations | Q36366489 |
| | Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer | Q37090628 |
| | Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer | Q37274280 |
| | Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? | Q37651794 |
| | Significance of thymidylate synthase for resistance to pemetrexed in lung cancer | Q39790341 |
| | Histological typing of lung and pleural tumours: third edition | Q43080931 |
| | The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer | Q43198701 |
| | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study | Q43274035 |
| | EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment | Q45244872 |
| | Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 |
| | Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population. | Q54595873 |
| P433 | issue | 2 | |
| P921 | main subject | adenosquamous carcinoma | Q3658380 |
| P304 | page(s) | 239-246 | |
| P577 | publication date | 2012-09-21 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung | |
| P478 | volume | 26 | |